Search

Your search keyword '"Kelly, Virginia"' showing total 18 results
Start Over Author "Kelly, Virginia" Journal blood
18 results on '"Kelly, Virginia"'

1. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Author

Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P., Cashen, Amanda F., Weaver, David T., Kelly, Virginia M., Turnbull, Barry, and Stilgenbauer, Stephan

Published
2018
Full Text
View/download PDF

2. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Author

Horwitz, Steven M., Koch, Raphael, Porcu, Pierluigi, Oki, Yasuhiro, Moskowitz, Alison, Perez, Megan, Myskowski, Patricia, Officer, Adam, Jaffe, Jacob D., Morrow, Sara N., Allen, Kerstin, Douglas, Mark, Stern, Howard, Sweeney, Jennifer, Kelly, Patrick, Kelly, Virginia, Aster, Jon C., Weaver, David, Foss, Francine M., and Weinstock, David M.

Published
2018
Full Text
View/download PDF

6. Results from the Phase 3 DUOTM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Author

Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone Jean, Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott D, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P, Cashen, Amanda, Kelly, Virginia, Turnbull, Barry, and Stilgenbauer, Stephan

Published
2017
Full Text
View/download PDF

9. Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

Author

Khoury, H. Jean, primary, Gambacorti-Passerini, Carlo, additional, Kantarjian, Hagop M., additional, Kim, Dong-Wook, additional, Marin, David, additional, Dorlhiac-Llacer, Pedro E, additional, Zaritskey, Andrey, additional, Navarro, Juan, additional, Bullorsky, Eduardo O, additional, Assouline, Sarit, additional, Leip, Eric, additional, Kelly, Virginia, additional, Turnbull, Kathleen, additional, Besson, Nadine, additional, and Cortes, Jorge E, additional

Published
2012
Full Text
View/download PDF

10. Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Author

Cortes, Jorge E., primary, Kantarjian, Hagop M., additional, Kim, Dong-Wook, additional, Turkina, Anna G, additional, Shen, Zhi-Xiang, additional, Khoury, H. Jean, additional, Brümmendorf, Tim H, additional, Schafhausen, Philippe, additional, Vellenga, Edo, additional, Pasquini, Ricardo, additional, Mathews, Vikram, additional, Masszi, Tamas, additional, Durrant, Simon, additional, Porkka, Kimmo, additional, Leip, Eric, additional, Kelly, Virginia, additional, Besson, Nadine, additional, and Gambacorti-Passerini, Carlo, additional

Published
2012
Full Text
View/download PDF

11. Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Author

Cortes, Jorge E., primary, Khoury, H. Jean, additional, Lipton, Jeff H, additional, Gambacorti-Passerini, Carlo, additional, Brümmendorf, Tim H, additional, Kim, Dong-Wook, additional, Leip, Eric, additional, Kelly, Virginia, additional, Besson, Nadine, additional, Turnbull, Kathleen, additional, and Kantarjian, Hagop M., additional

Published
2012
Full Text
View/download PDF

14. Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors

Author

Khoury, H. Jean, primary, Cortes, Jorge E, additional, Gambacorti-Passerini, Carlo, additional, Kim, Dong-Wook, additional, Zaritskey, Andrey, additional, Hochhaus, Andreas, additional, Leip, Eric, additional, Besson, Nadine, additional, Kelly, Virginia, additional, and Brümmendorf, Tim H, additional

Published
2011
Full Text
View/download PDF

15. Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Author

Kantarjian, Hagop M, primary, Cortes, Jorge E, additional, Kim, Dong-Wook, additional, Khoury, H. Jean, additional, Brümmendorf, Tim H, additional, Porkka, Kimmo, additional, Martinelli, Giovanni, additional, Durrant, Simon, additional, Leip, Eric, additional, Besson, Nadine, additional, Kelly, Virginia, additional, and Gambacorti-Passerini, Carlo, additional

Published
2011
Full Text
View/download PDF

16. Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib

Author

Khoury, H. Jean, primary, Kim, Dong-Wook, additional, Zaritskey, Andrey, additional, Gambacorti-Passerini, Carlo, additional, Hochhaus, Andreas, additional, Navarro, Juan, additional, Rapoport, Aaron P., additional, Dorlhiac-Llacer, Pedro Enrique, additional, Zanichelli, Maria, additional, Kelly, Virginia, additional, Besson, Nadine, additional, McMullan, Trevor, additional, Kantarjian, Hagop M., additional, and Cortes, Jorge E., additional

Published
2010
Full Text
View/download PDF

17. Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.

Author

Gambacorti-Passerini, Carlo, primary, Khoury, H. Jean, additional, Pinczowski, Helio, additional, Masszi, Tamas, additional, Kim, Dong-Wook, additional, Zanichelli, Maria, additional, Martinelli, Giovanni, additional, Kelly, Virginia, additional, Besson, Nadine, additional, McMullan, Trevor, additional, Brummendorf, Tim H., additional, and Cortes, Jorge E., additional

Published
2010
Full Text
View/download PDF

18. Results from the Phase 3 DUOTMTrial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Author

Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone Jean, Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott D, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P, Cashen, Amanda, Kelly, Virginia, Turnbull, Barry, and Stilgenbauer, Stephan

Abstract

Background: Despite the recent development of novel targeted therapies to treat chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), the disease remains incurable and many patients will eventually relapse despite optimal treatment. Additional therapies targeting novel pathways are needed for patients with relapsed/refractory CLL/SLL. Duvelisib (DUV) is an oral dual inhibitor of PI3K-δ and PI3K-γ being developed for the treatment of advanced B-cell malignancies, including CLL/SLL. In a Phase 1 study, the overall response rate (ORR) for DUV monotherapy in relapsed/refractory CLL/SLL (n=55) was 56% (with 1 complete response [CR]) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. Based on the safety and efficacy findings in this study, DUV 25 mg twice daily (BID) was selected as the recommended Phase 2 dose (RP2D) in CLL/SLL (O'Brien, ASH 2015). Herein we report the blinded baseline characteristics and disease history from DUO™, a Phase 3 randomized study evaluating DUV monotherapy vs ofatumumab (OFA) monotherapy in patients with relapsed or refractory CLL/SLL. The DUO study completed enrollment in December 2015 and the protocol-defined final analysis (185 progression-free survival [PFS] events) is in progress; the complete trial results will be presented at the American Society of Hematology 59thAnnual Meeting in December.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results